Avandia, a Case of Deja Vu all over again
Similar Posts
NIMH Chief Child/Adoles Research Blows Wind out TeenScreen Sails_ Los Angeles Times
"Some politicians, public health officials, mental health activists and pharmaceutical companies have worked to establish mental-health screening programs in schools and the community….Researchers and clinicians, meanwhile, say they are far from having developed accurate predictors of a child developing depression. The younger the child, the murkier the crystal ball."
Worldwide Drug Industry Ailing – PhaRMA Giants Reeling Blockbuster Drugs Found Hazardous
Worldwide Drug Industry Ailing – PhaRMA Giants Reeling Blockbuster Drugs Found Hazardous Sat, 18 Dec 2004 Daily headlines provide confirmatory evidence supporting what critics of the drug industry have been say:ing for years. First, as The New York Times notes in one of its 4 articles about the latest “unexpected”…
Antipsychotics Killed at least 45 Children_FDA Not Concerned –USA Today
"I trusted the doctors, I trusted the FDA … and I feel betrayed by both," says Erin Evans, the mother of Rex who was prescribed the ‘atypical’ antipsychotic, Risperdal (risperidone) at age 8.
FDA Foot Dragging – Three Months After Expert Panel Urged "Black Box" Warnings for Antidepressants, No Action
FDA Foot Dragging – Three Months After Expert Panel Urged “Black Box” Warnings for Antidepressants, No Action Thu, 23 Dec 2004 Why is the FDA failing to enforce the "Black Box" warnings on SSRI antidepressant drug labels? When questioned by the NJ Star Ledger, Robert Temple, director of the FDA’s…
What Parents Aren’t Being told about their Kids Antidepressants – A Suicide Side-Effect? – SF Chronicle
What Parents Aren’t Being told about their Kids Antidepressants – A Suicide Side-Effect? – SF Chronicle Sat, 10 Jan 2004 An in-depth article in The San Francisco Chronicle reveals how the hidden hazards of SSRIs put adolescents’ lives in danger. For one 16 year old teenager, Paxil posed greater risks…
GlaxoSmithKline CEO: "We had to absorb a number of hits"
GlaxoSmithKline CEO: “We had to absorb a number of hits” Mon, 16 Feb 2004 Antidepressant drug safety issues are beginning to have a financial impact. Dow Jones reports: “GlaxoSmithKline PLC said its net income fell 6% in the fourth quarter, hurt by previously announced legal costs related to its anti-inflammatory…